[177Lu]Lu-DOTAZOL在成骨性转移患者中的生物分布与治疗后剂量学分析:首次结果
该研究纳入4例成骨性转移患者(年龄64–83岁),给予平均5968±64 MBq的[177Lu]Lu-DOTAZOL,通过系列平面全身显像和血样分析生物分布与正常器官吸收剂量。结果显示骨骼摄取随时间增加,骨吸收剂量最高(成骨细胞3.33 mSv/MBq),肾脏剂量较低(0.490 mSv/MBq),与临床前数据一致,提示该药是有前景的骨转移核素治疗药物。
要点
- 骨骼是[177Lu]Lu-DOTAZOL的主要摄取器官,成骨细胞平均吸收剂量达3.33 mSv/MBq。
- 肾脏吸收剂量较低(0.490 mSv/MBq),红骨髓0.461 mSv/MBq,膀胱壁0.322 mSv/MBq。
- 生物分布与临床前数据一致,支持进一步评估疗效与安全性。
核心结论
- [177Lu]Lu-DOTAZOL在骨中吸收剂量最高、肾脏剂量低,是骨转移核素治疗的有前景药物。
- 需进一步研究评估其临床疗效与安全性。
研究设计与样本
- 纳入4例成骨性转移患者(年龄64–83岁),继发于转移性去势抵抗性前列腺癌或支气管癌。
- 给予平均剂量5968±64 MBq(161.3 mCi)的[177Lu]Lu-DOTAZOL。
- 于注射后20分钟及3、24、167小时行系列平面全身显像,并于20分钟及3、8、24、167小时采血。
- 采用基于血液的间接法测定骨髓自身剂量,用Cloutier动态膀胱模型(4小时排尿间隔)计算膀胱壁滞留时间。
- 使用OLINDA/EXM 2.0软件经双指数曲线拟合计算源器官滞留时间和器官吸收剂量。
主要发现
- 定性生物分布显示肾脏早期高摄取并快速清除,至注射后24小时活性已很低。
- 骨骼活性随时间逐渐增加,平均滞留时间以骨骼最高,其次为肾脏。
- 平均器官吸收剂量:成骨细胞3.33 mSv/MBq,肾脏0.490 mSv/MBq,红骨髓0.461 mSv/MBq,膀胱壁0.322 mSv/MBq。
- 生物分布和正常器官吸收剂量与临床前数据一致。
临床怎么用
- 该药骨骼吸收剂量高而肾脏剂量低,可能适合用于骨转移的核素治疗。
- 目前仅为首次人体剂量学结果,临床疗效与安全性尚待进一步研究。
局限性
- 样本量仅4例,年龄范围64–83岁,继发于前列腺癌或支气管癌。
- 骨髓自身剂量由基于血液的间接法测定。
- 膀胱壁滞留时间基于4小时排尿间隔的模型假设。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preclinical biodistribution and dosimetric analysis of [177Lu]Lu-DOTAZOL suggest the bisphosphonate zoledronate as a promising new radiopharmaceutical for therapy of bone metastases. We evaluated biodistribution and normal organ absorbed doses resulting from therapeutic doses of [177Lu]Lu-DOTAZOL in patients with metastatic skeletal disease. METHOD: Four patients with metastatic skeletal disease (age range, 64-83 years) secondary to metastatic castration-resistant prostate carcinoma or bronchial carcinoma were treated with a mean dose of 5968 ± 64 MBq (161.3 mCi) of [177Lu]Lu-DOTAZOL. Biodistribution was assessed with serial planar whole body scintigraphy at 20 min and 3, 24, and 167 h post injection (p.i.) and blood samples at 20 min and 3, 8, 24, and 167 h p.i. Percent of injected activity in the blood, kidneys, urinary bladder, skeleton, and whole body was determined. Bone marrow self-dose was determined by an indirect blood-based method. Urinary bladder wall residence time was calculated using Cloutier's dynamic urinary bladder model with a 4-h voiding interval. OLINDA/EXM version 2.0 (Hermes Medical Solutions, Stockholm, Sweden) software was used to determine residence times in source organs by applying biexponential curve fitting and to calculate organ absorbed dose. RESULTS: Qualitative biodistribution analysis revealed early and high uptake of [177Lu]Lu-DOTAZOL in the kidneys with fast clearance showing minimal activity by 24 h p.i. Activity in the skeleton increased gradually over time. Mean residence times were found to be highest in the skeleton followed by the kidneys. Highest mean organ absorbed dose was 3.33 mSv/MBq for osteogenic cells followed by kidneys (0.490 mSv/MBq), red marrow (0.461 mSv/MBq), and urinary bladder wall (0.322 mSv/MBq). The biodistribution and normal organ absorbed doses of [177Lu]Lu-DOTAZOL are consistent with preclinical data. CONCLUSION: [177Lu]Lu-DOTAZOL shows maximum absorbed doses in bone and low kidney doses, making it a promising agent for radionuclide therapy of bone metastasis. Further studies are warranted to evaluate the efficacy and safety of radionuclide therapy with [177Lu]Lu-DOTAZOL in the clinical setting.
引用
- Khawar A, Eppard E, Roesch F, et al. Biodistribution and post-therapy dosimetric analysis of [177Lu]Lu-DOTAZOL in patients with osteoblastic metastases: first results. EJNMMI Res. 2019. PMID: 31781962. doi:10.1186/s13550-019-0566-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。